

FLAMEL TECHNOLOGIES

November 2011

Forward Looking Statements

The following presentation regarding Flamel Technologies SA includes a number of matters, particularly as related to the status of various research projects and technology platforms, that constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The presentation reflects the current views of Flamel's management with respect to future events and is subject to risks and uncertainties that could cause actual results to differ materially from those contemplated in such forward-looking statements. These risks include risks that products in the development stage may not achieve scientific objectives or milestones or meet stringent regulatory requirements, uncertainties regarding market acceptance of products in development, the impact of competitive products and pricing, and the risks associated with Flamel's reliance on outside parties and key strategic alliances. These and other risks are described more fully in Flamel's public filings. Except as required by law, Flamel does not intend, and disclaims any duty or obligation, to update or revise any forward-looking statements contained in this presentation to reflect new information, future events or otherwise.

Our Value Proposition

- Two complementary drug delivery technologies validated by many pharma partnerships
- A diversified portfolio of partnered products addressing large markets
- FDA-approved manufacturing facility provides a plug-and-play option for our partners
- Strong cash position
- Significant corporate profitability can be achieved with a modest number of projects continuing further in the clinic and to market

Recent News

- Licensing agreement for application of Micropump to two molecules for pain indications announced in April 2011
  - ✓ $3 million upfront license fee
  - ✓ Mid-single digit royalties
- Licensing agreement for Micropump formulation of CNS drug
  - ✓ $500,000 upfront fee
  - ✓ Mid-single digit royalties
- Licensing Agreement with Eagle Pharmaceuticals for subcutaneous formulation of tigecycline.
- Successfully completed strong new supply agreement with GSK for Coreg CR microparticles.

Partnerships Drive Our Growth

- Flamel works with leading companies to provide the best drug delivery solutions to improve existing products and bringing new products to market
- We currently work with 8 of the top 25 pharmaceutical companies in the world
- Leverage partner's expertise to develop our platforms



Merck Serono Project Update

- Milestone achieved in clinical development of next generation Interferon-beta 1-a with Merck Serono
- Flamel received € 3 million after achieving its first clinical milestone
- Interferon beta is indicated for the treatment of multiple sclerosis and currently is dosed thrice weekly via subcutaneous injection
  - Rebif®, Betaseron, and Avonex revenues were over $6.3 billion in 2010
  - Currently only Avonex is dosed once-weekly, via intramuscular injection

New Joint Development Initiative

- Working with development stage companies to create controlled release formulations of first in class molecules
- Flamel benefits from joint ownership
  - Greater economic participation
  - Limited out-of-pocket expense limits potential risk
  - Access to novel molecules addressing large markets with high unmet medical needs
- Two programs have been announced thus far:
  - Theralpha, SA : Acid Sensing Ion Channel Inhibitor
  - Digna Biotech: Multiple programs

Theralpha, SA

- Groundbreaking IP covering Acid Sensing Ion Channels (ASIC's)
  - Trigger body's recognition of inflammatory response (associated with lower pH).
- Inhibition of ASICs has been shown to reduce pain associated with inflammation
  - Targeted indications include:
    - Post-Operative Pain;
    - Osteoarthritis; and
    - Fybromyalgia
- High unmet medical need for effective non-narcotic pain relief

Digna Biotech

- Develops and commercialize the IP generated at CIMA (Center for Applied Medical Research)
  - Largest private biomedical research center in Spain
- Multiple Product Development Relationship covering:
  - Medusa formulations of Transforming Growth Factor Beta-1 Inhibitors (TGF-beta 1 inhibitors)
    - P144 to be tested in treatment of organ fibrosis and macular degeneration, among other indications
    - P17 to be tested in treatment of cirrhosis, prevention of angiogenesis and metastasis
  - Micropump formulation of Methylthiadenosine (MTA)
    - Potent immunomodulator with neuroprotective properties to be evaluated in treatment of MS and other CNS disorders

Partnership Portfolio (as of November 2011)



One Straightforward Goal

Deliver the right molecule in the right place at the right time at the right dose

Flamel's Technology Platforms



Medusa Technology

- Medusa polymer is made of glutamic acid and Vitamin E
- The polymer is amphiphilic and spontaneously forms stable nanoparticles in water
- Complexes are robust over a wide range of pH values and can be stored as either stable liquid or stable dry forms that can be easily reconstituted in water



What Medusa Delivers

- The Medusa Ubiquitous Polymer has unfilled hydrophobic bonding sites
- Most biologics have hydrophobic patches; they self-associate to bonding sites when introduced to solution with Medusa polymer
- Biologics are adsorbed without covalent bonds, and so maintain full bioactivity
  - Solubility and stability are enhanced while aggregation is prevented
- When injected, endogenous proteins replace the therapeutic molecule on the polymer, releasing the drug at a controlled rate
- Suitable for combination products
- Full safety and toxicology package on the polymer limits risk of development

Delivering the Right Molecules

- Proteins and peptides: IV, subcutaneous, and oral delivery
  - Multiple IV and subcutaneous projects underway with partners
  - Ongoing oral delivery project with top-5 pharma company begun in 2007, program renewed and animal testing being conducted
- Antigens for vaccines
  - Proof of concept demonstrated with a top-20 pharma partner
  - Significant driver of deals going forward: in negotiations with leading vaccine players for prophylactic and therapeutic vaccines
- Already marketed molecules: Biosimilars → Biobetters
  - Lower efficacy risk
  - Interferons, Insulin, Blood Factors, Carvedilol
- New biological entities
  - Medusa is being applied to unstable, insoluble molecules that might otherwise be shelved

The Right Place in the Right Amount

- Medusa offers better controlled release
  - Subcutaneous products have lower $C_{max,}$ no “burst effect”
  - Higher sustained concentrations
  - Fewer side-effects
  - Biologics maintain full bioactivity

- Medusa offers better extended release
  - Subcutaneous products enter the bloodstream slowly
    - Up to 1-2 weeks
  - IV solutions easier to handle
    - Improved patient and caregiver convenience
    - Stability and anti-aggregation advantages

Medusa Project Portfolio

- Our portfolio of feasibility studies is well diversified
- Balance between lower-risk reformulations and higher-risk NMEs
- Successful feasibility studies feed our pipeline



Large Addressable Markets

- Medusa platform is applicable to a wide variety of molecule types and therapeutic areas
- Clinical development studies are funded by partners
- Clinical development studies addressing a total > $14 billion in market opportunities

Global 2010 market value for clinical-stage Medusa-based compounds (in $ billion)



IFN Alpha-2b XL

- Novel formulation of recombinant Interferon alpha-2b based using Medusa, fully owned by Flamel
- Reduction in side effects vs. PegIntron in Phase 1
- Significant reduction in viral load for a subgroup of Genotype 1 receiving 27 MIU vs. PegIntron
- Funded and conducted by French Government Agency Specializing in Hepatitis
- Recruitment slower than anticipated but has increased with addition of new clinics
- Poster to be presented at 2011 AASLD
  - Results confirmed previous viral load reduction and also advantageous safety profile, with far fewer adverse events among patients receiving IFN-Alpha XL

IFN Alpha-2b XL Phase 2a



WBD: weight-based dosing

Micropump Technology

- Multiple-dose system containing 5,000 to 10,000 microparticles per capsule or tablet
- Microparticles are released in the stomach and pass into the small intestine
- Drug released at an adjustable rate:
  - controlled for Micropump I
  - delayed for Micropump II
- Both types of Micropump particles can be used separately or together to provide highly specialized delivery profiles



What Micropump Delivers

- Micropump offers best-in-class oral drug delivery solutions for small molecule formulations:
  - Liquid formulations
  - Combination products
  - Suitable for all patient populations

- Each microparticle delivers active ingredient separately

- Combinations of different microparticles offers precise control of absorption

Delivering the Right Molecules

- Microparticles control the absorption rate
  - Controlled-release products
  - Taste-masking of bad-tasting materials
    - Microparticles dosed in sachet or liquid suspension
    - Rapidly dissolving tablets

- High loading ratio of active to polymer coating
  - Important for products with large daily dosing
  - Avoids the problem of dose-dumping

- Trigger-Lock Adaptation designed to prevent tampering with scheduled drugs

The Right Place in the Right Amount

- Micropump formulations are released at the preferred site of absorption
  - Stomach
  - Small intestine

- Micropump uses microparticles:
  - Inter-patient and intra-patient variability is minimized
  - Peak:trough ratio is minimized
  - Solubility gains mean plasma levels increased

Controlled Release Opioids

- Trigger-Lock Adaptation designed to prevent misuse of scheduled drugs such as narcotic analgesics
- Micropump particles cannot be crushed
- Additional modifications tailored to prevent other less publicized methods of foiling controlled release systems
- Provides either bioequivalent or improved pharmacokinetics
- May be applied to novel; already-marketed; or off-patent molecules

Coreg CR Update

- Indicated for treatment of congestive heart failure (CHF) and treatment of left ventricular dysfunction following myocardial infarction (MI)
  - Total net sales of Coreg CR & Coreg as reported by GSK were $265 MM in 2010
- Partnered with GSK
  - Milestones; Royalties on Net Sales; and Supply agreement for production of microparticles
- Hatch-Waxman expired April 2010
- Flamel filed a Citizen's Petition with the FDA in April 2010
  - FDA Response Received and available at www.flamel.com
- Paragraph IV certification letters received from Lupin Pharmaceuticals and Anchen Pharmaceuticals
- New Supply Agreement completed October 2011 includes guaranteed minimums and expanded margins.

Financials

($ MM except per share)	3 months ended September 30, 2011
Total Revenue	10.43
Total Costs and Expenses	(9.19)
Income from Operations	1.24
Net Income	1.70
Diluted EPS	$ 0.07
Diluted Shares Outstanding	24.97 MM

Strong cash position

- As of September 30, 2011, cash and equivalents amounted to $29.5 MM